4 Biotech Stocks With Important Catalysts Approaching
December 5, 2012
Sarepta will announce 60 week clinical data confirming the 48 week data and seek accelerated approval from the FDA for eteplirsen. The release of the 60 week data could occur anytime and, if positive, would certainly propel the stock and give Sarepta more leverage for accelerated approval from the FDA.
Sentiment: Strong Buy
From the Bloomberg interview: "We will look for the right medical conferences to present updates. We did not apply a single rigorous analysis on a single endpoint. We collected two measures and prospectively defined that we would take the best score. Now we are just collecting a single measure. We won’t have the same level of detail on the six minute walk test for subsequent time points because we don’t have the corresponding biopsies to look at dystrophin levels."
Purposely ambiguous? And for what motivation?